• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by HCW Biologics Inc.

    6/8/26 4:11:48 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HCWB alert in real time by email
    Form D
    FORM D
    Notice of Exempt Offering of Securities

    UNITED STATES SECURITIES
    AND EXCHANGE COMMISSION
    Washington, D.C.

    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated Average burden hours per response: 4.0
    1. Issuer's Identity
    CIK (Filer ID Number)Previous Name(s)Checkbox checkedNoneEntity Type
    0001828673
    Radio button checkedCorporation
    Radio button not checked Limited Partnership
    Radio button not checked Limited Liability Company
    Radio button not checked General Partnership
    Radio button not checked Business Trust
    Radio button not checkedOther 
    Name of Issuer
     HCW Biologics Inc.
    Jurisdiction of Incorporation/Organization
    DELAWARE 
    Year of Incorporation/Organization
    Radio button checkedOver Five Years Ago
    Radio button not checkedWithin Last Five Years (Specify Year)
     
    Radio button not checkedYet to Be Formed
     
      
      
     
    2. Principal Place of Business and Contact Information
    Name of Issuer
     HCW Biologics Inc.
    Street Address 1Street Address 2
     2929 N COMMERCE PKWY
     
    CityState/Province/CountryZIP/Postal CodePhone No. of Issuer
     MIRAMAR
     FLORIDA
     
     33025
     954-842-2024 




    3. Related Persons

    Last NameFirst NameMiddle Name
    Wong
    Hing
    C.
    Street Address 1Street Address 2
     2929 N. Commerce Parkway 
     
    CityState/Province/CountryZIP/Postal Code
     Miramar
     FLORIDA
     33025
     
    Relationship:Checkbox checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     



    Last NameFirst NameMiddle Name
    Byam
    Rebecca
    Street Address 1Street Address 2
     2929 N. Commerce Parkway 
     
    CityState/Province/CountryZIP/Postal Code
     Miramar
     FLORIDA
     33025
     
    Relationship:Checkbox checkedExecutive OfficerCheckbox not checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     



    Last NameFirst NameMiddle Name
    Garrett
    Scott
    T.
    Street Address 1Street Address 2
     2929 N. Commerce Parkway 
     
    CityState/Province/CountryZIP/Postal Code
     Miramar
     FLORIDA
     33025
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     



    Last NameFirst NameMiddle Name
    Giles
    Lisa
    M.
    Street Address 1Street Address 2
     2929 N. Commerce Parkway 
     
    CityState/Province/CountryZIP/Postal Code
     Miramar
     FLORIDA
     33025
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     



    Last NameFirst NameMiddle Name
    Greene
    Rick
    S.
    Street Address 1Street Address 2
     2929 N. Commerce Parkway 
     
    CityState/Province/CountryZIP/Postal Code
     Miramar
     FLORIDA
     33025
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     



    Last NameFirst NameMiddle Name
    Flower
    Lee
    Street Address 1Street Address 2
     2929 N. Commerce Parkway 
     
    CityState/Province/CountryZIP/Postal Code
     Miramar
     FLORIDA
     33025
     
    Relationship:Checkbox checkedExecutive OfficerCheckbox not checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     



    Last NameFirst NameMiddle Name
    Rhode
    Peter
    Street Address 1Street Address 2
     2929 N. Commerce Parkway 
     
    CityState/Province/CountryZIP/Postal Code
     Miramar
     FLORIDA
     33025
     
    Relationship:Checkbox checkedExecutive OfficerCheckbox not checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     





    4. Industry Group
     Radio button not checkedAgriculture
    Banking & Financial Services
     Radio button not checked Commercial Banking
     Radio button not checked Insurance
     Radio button not checkedInvesting
     Radio button not checked Investment Banking
     Radio button not checked Pooled Investment Fund

     Radio button not checkedOther Banking & Financial Services
    Radio button not checked Business Services
    Energy
     Radio button not checked Coal Mining
     Radio button not checked Electric Utilities
     Radio button not checked Energy Conservation
     Radio button not checked Environmental Services
     Radio button not checked Oil & Gas
     Radio button not checked Other Energy
    Health Care
     Radio button checked Biotechnology
     Radio button not checked Health Insurance
     Radio button not checked Hospitals & Physicians
     Radio button not checked Pharmaceuticals
     Radio button not checked Other Health Care
       
       
       
      
    Radio button not checked Manufacturing
    Real Estate
     Radio button not checkedCommercial
     Radio button not checkedConstruction
     Radio button not checkedREITS & Finance
     Radio button not checkedResidential
    Radio button not checkedOther Real Estate
    Radio button not checked Retailing
    Radio button not checkedRestaurants
    Technology
    Radio button not checked Computers
    Radio button not checked Telecommunications
    Radio button not checked Other Technology
    Travel
    Radio button not checked Airlines & Airports
    Radio button not checked Lodging & Conventions
    Radio button not checked Tourism & Travel Services
    Radio button not checked Other Travel
    Radio button not checkedOther

      
       
    5. Issuer Size
    Revenue RangeAggregate Net Asset Value Range
    Radio button not checkedNo RevenuesRadio button not checked No Aggregate Net Asset Value
    Radio button not checked $1 - $1,000,000Radio button not checked$1 - $5,000,000
    Radio button not checked $1,000,001 - $5,000,000Radio button not checked $5,000,001 - $25,000,000
    Radio button not checked$5,000,001 - $25,000,000Radio button not checked $25,000,001 - $50,000,000
    Radio button not checked$25,000,001 - $100,000,000Radio button not checked $50,000,001 - $100,000,000
    Radio button not checked Over $100,000,000Radio button not checked Over $100,000,000
    Radio button checked Decline to Disclose Radio button not checkedDecline to Disclose
    Radio button not checked Not ApplicableRadio button not checked Not Applicable

     
    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)
    Checkbox not checkedRule 504(b)(1) (not (i), (ii)
    or (iii))
    Checkbox checkedRule 506(b)      
    Checkbox not checkedRule 504 (b)(1)(i) Checkbox not checkedRule 506(c)
    Checkbox not checkedRule 504 (b)(1)(ii) Checkbox not checkedSecurities Act Section 4(a)(5)
    Checkbox not checkedRule 504 (b)(1)(iii)Checkbox not checkedInvestment Company Act Section 3(c)
     
     

    7. Type of Filing
    Checkbox checked New Notice Date of First Sale 
    2026-05-21
    Checkbox not checked First Sale Yet to Occur
    Checkbox not checked Amendment


     
     
    8. Duration of Offering
    Does the Issuer intend this offering to last more than one year? Radio button not checked Yes Radio button checked No
     
     
    9. Type(s) of Securities Offered (select all that apply)
    Checkbox not checkedPooled Investment Fund InterestsCheckbox checkedEquity
    Checkbox not checkedTenant-in-Common Securities Checkbox not checkedDebt
    Checkbox not checkedMineral Property SecuritiesCheckbox checkedOption, Warrant or Other Right to Acquire Another Security
    Checkbox checkedSecurity to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire SecurityCheckbox not checkedOther (describe)
     
     
     
    10. Business Combination Transaction
    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? Radio button not checked Yes Radio button checked No
    Clarification of Response (if Necessary)
     
     
     
    11. Minimum Investment
    Minimum investment accepted from any outside investor$
     0
    USD

    12. Sales Compensation
    Recipient Recipient CRD NumberCheckbox not checkedNone
     
     
    (Associated) Broker or DealerCheckbox not checkedNone(Associated) Broker or Dealer CRD Number  Checkbox not checkedNone
     
     
    Street Address 1Street Address 2
     
     
    City State/Province/CountryZIP/Postal Code
     
     
     
    State(s) of Solicitation Checkbox not checkedAll States
     



    13. Offering and Sales Amounts
     
    Total Offering Amount $
    4000000
    USDCheckbox not checkedIndefinite
    Total Amount Sold $
    4000000
    USD
    Total Remaining to be Sold $
    0
    USDCheckbox not checkedIndefinite
    Clarification of Response (if Necessary)
      
     
    14. Investors

    Checkbox not checkedSelect if securities in the offering have been or may be sold to persons who do not qualify as accredited investors,
    Number of such non-accredited investors who already have invested in the offering
       
      Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    7
     
    15. Sales Commissions & Finders’ Fees Expenses
    Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
    Sales Commissions$
    0
    USDCheckbox not checkedEstimate
    Finders' Fees$
    0
    USDCheckbox not checkedEstimate
    Clarification of Response (if Necessary)
     
     

    16. Use of Proceeds
    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
     $ 
    0
    USDCheckbox not checkedEstimate
    Clarification of Response (if Necessary)
     

    Signature and Submission
     
    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.
    Terms of Submission 
     In submitting this notice, each Issuer named above is: 
     
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, the information furnished to offerees.
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).
     
    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.
    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.
     
    IssuerSignatureName of SignerTitleDate
    HCW Biologics Inc.Hing C. WongHing C. WongChief Executive Officer2026-06-08




    Get the next $HCWB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HCWB

    DatePrice TargetRatingAnalyst
    11/19/2021$10.00Buy
    EF Hutton
    More analyst ratings

    $HCWB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    EF Hutton initiated coverage on HCW Biologics with a new price target

    EF Hutton initiated coverage of HCW Biologics with a rating of Buy and set a new price target of $10.00

    11/19/21 8:39:08 AM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HCWB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen

    Positions the Company to participate in fast-growing, multi-billion-dollar CAR-T immunotherapy market Recently published data suggest that HCW9206 may reduce CAR-T production costs and improve therapeutic efficacies, with the potential to support curative outcomes Company plans to commercialize the reagents through corporate partners focused on CAR-T and NK-cell therapies, including developers and manufacturers MIRAMAR, Fla., May 27, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company developing first-in-class fusion immunotherapeutics for autoimmune diseases, cancer, and senescence-associated dysplasia, today announced t

    5/27/26 7:45:00 AM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    E.F. Hutton & Co. Serves as Sole Placement Agent on HCW Biologics Inc. $4.0 Million Private Placement

    NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co. ("E.F. Hutton"), an investment banking and financial advisory firm headquartered in New York City, today announced that it acted as the sole placement agent in connection with a $4.0 million private placement for HCW Biologics Inc. ("HCW Biologics" or the "Company") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics designed to treat diseases driven by chronic inflammation, including autoimmune disorders, cancer, and senescence-associated conditions. Joseph T. Rallo, Chief Executive Officer of E.F. Hutton & Co., commented, "We are pleased to have partnered with HCW Biolo

    5/22/26 4:02:37 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HCW Biologics Inc. Announces Pricing of Approximately $4.0 Million Private Placement Offering At-the-Market Under Nasdaq Rules

    MIRAMAR, Fla., May 21, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics"), (NASDAQ:HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to treat autoimmune, cancer and senescence-associated dysplasia, today announced the pricing of its private placement of an aggregate of 2,846,975 units at a purchase price of $1.405 per unit priced at-the-market under Nasdaq rules to a group of healthcare investors (the "Investors"). Each unit consists of (i) one share of common stock at a purchase price of $1.28 per share (or, in lieu thereof, one pre-funded warrant at a purchase price of $1.2799 per pre-funded warrant with an e

    5/21/26 9:53:05 AM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HCWB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Wong Hing C bought $160,000 worth of shares (113,879 units at $1.41), increasing direct ownership by 23% to 615,790 units (SEC Form 4)

    4 - HCW Biologics Inc. (0001828673) (Issuer)

    5/27/26 7:26:32 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Garrett Scott T bought $250,000 worth of shares (177,936 units at $1.41) (SEC Form 4)

    4 - HCW Biologics Inc. (0001828673) (Issuer)

    5/27/26 7:25:09 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Byam Rebecca bought $20,000 worth of shares (14,235 units at $1.41), increasing direct ownership by 33% to 57,245 units (SEC Form 4)

    4 - HCW Biologics Inc. (0001828673) (Issuer)

    5/27/26 7:23:30 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HCWB
    SEC Filings

    View All

    SEC Form D filed by HCW Biologics Inc.

    D - HCW Biologics Inc. (0001828673) (Filer)

    6/8/26 4:11:48 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-1 filed by HCW Biologics Inc.

    S-1 - HCW Biologics Inc. (0001828673) (Filer)

    6/8/26 10:10:24 AM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HCW Biologics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - HCW Biologics Inc. (0001828673) (Filer)

    6/1/26 7:30:18 AM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HCWB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Wong Hing C bought $160,000 worth of shares (113,879 units at $1.41), increasing direct ownership by 23% to 615,790 units (SEC Form 4)

    4 - HCW Biologics Inc. (0001828673) (Issuer)

    5/27/26 7:26:32 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Garrett Scott T bought $250,000 worth of shares (177,936 units at $1.41) (SEC Form 4)

    4 - HCW Biologics Inc. (0001828673) (Issuer)

    5/27/26 7:25:09 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Byam Rebecca bought $20,000 worth of shares (14,235 units at $1.41), increasing direct ownership by 33% to 57,245 units (SEC Form 4)

    4 - HCW Biologics Inc. (0001828673) (Issuer)

    5/27/26 7:23:30 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HCWB
    Leadership Updates

    Live Leadership Updates

    View All

    HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights

    MIRAMAR, Fla., April 01, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its fourth quarter and fiscal year ended December 31, 2023.  Dr. Hing C. Wong, Founder and CEO of HCW Biologics, stated, "These are exciting times at HCW Biologics. We achieved two major clinical milestones, with the completion of the Phase 1 clinical study to evaluate HCW9218 in solid tumors and the Phase 1b stu

    4/1/24 4:10:32 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HCWB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by HCW Biologics Inc.

    SC 13D/A - HCW Biologics Inc. (0001828673) (Subject)

    11/22/24 4:53:35 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HCWB
    Financials

    Live finance-specific insights

    View All

    HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results

    MIRAMAR, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company focused on developing transformative fusion immunotherapeutics to treat autoimmune disease, cancer and senescence-associated dysplasia, today reported financial results and recent business highlights for the three months ended March 31, 2026. The Company remains on track to provide preliminary clinical data readout from the first two dose levels of the Phase 1 clinical study evaluating HCW9302 in alopecia areata in the first half of 2026. There are two clinical sites actively enrolling patients, and enrollment has been on schedule.

    5/14/26 4:25:00 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results

    MIRAMAR, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation, today reported financial results and recent business highlights for its three months ended December 31, 2025. On November 17, 2025, the Company initiated its first-in-human clinical trial to evaluate HCW9302, the lead product candidate for the Company's program to develop treatments for autoimmune disorders and proinflammatory diseases, in patients with areata alopecia. HCW9302 is a subcutaneously injectable, first-i

    3/31/26 5:05:40 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results

    MIRAMAR, Fla., Aug. 18, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its second quarter ended June 30, 2025.  On May 15, 2025, the Company closed an equity offering with gross proceeds of $5.0 million with a single institutional investor. Dr. Hing Wong, Founder and CEO, stated, "We are pleased to have completed a successful $5.0 million equity offering in a challenging market with

    8/18/25 2:44:03 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care